Paraneoplastic Brainstem Syndromes

Introduction to Paraneoplastic Syndromes

• The American Thoracic Society recommends that paraneoplastic brainstem syndromes be treated with priority given to tumor treatment, combined with immunotherapy for stabilization of neurological symptoms, as these syndromes are autoimmune neurological disorders caused by cancer, primarily small cell lung cancer 1, 2

Pathophysiology and Clinical Characteristics

• Paraneoplastic brainstem syndromes occur through T-cell mediated autoimmune mechanisms, not direct tumor effects, and can manifest with brainstem encephalitis, cerebellar degeneration, and opsoclonus-myoclonus, with serious complications including epilepsy, status epilepticus, and central respiratory failure 1, 2

Relevant Paraneoplastic Antibodies

• The presence of anti-Hu antibodies is diagnostic but not pathogenic, with a sensitivity of 82% and specificity of 99% for diagnosis, and is the most common paraneoplastic neurological syndrome in lung cancer, with >90% of cases associated with small cell lung cancer 1, 2
• Anti-Yo syndrome is more commonly associated with ovarian and breast cancer but can occur in small cell lung cancer, with primary clinical manifestations including brainstem and cerebellar abnormalities, and anti-Yo antibodies are directly involved in the pathogenic mechanism, causing neuronal apoptosis 1, 2

Treatment Strategies

• The American College of Chest Physicians recommends that treatment of the underlying cancer is the primary and most important approach, as a favorable response to cancer therapy positively influences the course of paraneoplastic syndromes, and successful tumor therapy often improves paraneoplastic symptoms 1, 2
• First-line immunotherapy should be started early, without waiting for antibody test results, and includes IV immunoglobulin, high-dose IV methylprednisolone, and plasmapheresis, which have shown clinical benefits 1, 2
• Second-line immunotherapy, including rituximab and cyclophosphamide, should be considered if there is no improvement after 2-4 weeks of first-line therapy 1, 2

Prognosis and Limitations of Therapy

• The European Hematology Association notes that immunosuppression can transiently stabilize paraneoplastic syndromes but rarely provides long-term improvement, and some neurological symptoms or signs may be irreversible due to the low regenerative capacity of the central nervous system 3
• Permanent neurological sequelae should not be interpreted as treatment failure, and response to immunotherapy is better for antibodies targeting surface antigens than intracellular antigens 3

Management of Paraneoplastic Syndromes

Classification and General Approach

• The American College of Chest Physicians suggests that paraneoplastic syndromes can be broadly categorized into two main mechanisms: hormonally-based syndromes and immunologically-based syndromes 4, 5, 6

Management of Specific Paraneoplastic Syndromes

• Ectopic Cushing Syndrome is commonly associated with small cell lung cancer and bronchial carcinoid, and its diagnostic approach involves excluding iatrogenic causes of Cushing syndrome before biochemical testing, with initial testing using 24-hour urinary free cortisol, late-night salivary cortisol, or dexamethasone suppression test 5
• Carcinoid Syndrome is associated with neuroendocrine tumors, particularly bronchial carcinoids, and its diagnostic approach involves measuring 24-hour urinary 5-HIAA and serum chromogranin A, with management including surgical resection when feasible and somatostatin analogs for metastatic disease 4, 6
• Anti-Hu Syndrome is the most common paraneoplastic neurological syndrome in lung cancer, particularly small cell lung cancer, and its management involves treatment of the underlying malignancy as the primary approach, with immunosuppressive therapy providing transient stabilization but rarely long-term improvement 4, 7
• Dermatomyositis is associated with lung cancer and often diagnosed within 1 year of cancer diagnosis, with diagnostic criteria including progressive symmetrical proximal muscle weakness, elevated muscle enzymes, and characteristic skin findings, and management involving corticosteroids as first-line therapy and additional immunosuppressive agents for refractory cases 8

General Management Principles

• Early recognition and diagnosis are critical to improve outcomes, with prompt identification leading to detection of occult malignancies at treatable stages 8
• Treating the underlying malignancy is the primary approach, with successful cancer treatment often improving paraneoplastic symptoms 4
• Syndrome-specific therapy based on mechanism is essential, with immunosuppression using IVIg, corticosteroids, and cyclophosphamide for immunologic paraneoplastic syndromes, and targeted therapies to block hormone effects for hormonal paraneoplastic syndromes 4, 5, 7

Management of Paraneoplastic Syndromes

Diagnostic Approach

• The American Thoracic Society recommends confirming the diagnosis while initiating treatment in parallel with cancer workup to avoid delays, with a comprehensive approach including imaging and tissue biopsy when indicated 9, 10, 11
• The European League Against Rheumatism suggests ruling out metastases, unrelated rheumatic diseases, and checkpoint inhibitor-related immune adverse events as differential diagnoses through imaging and tissue biopsy when indicated 11

Treatment Strategy

• The American College of Chest Physicians recommends first-line immunotherapy, including IV immunoglobulin (IVIg) and high-dose IV methylprednisolone, for neurologic/immunologic paraneoplastic syndromes, with IVIg being particularly effective when administered within 1 month of symptom onset 9, 12
• The American College of Rheumatology suggests second-line immunotherapy, including rituximab, cyclophosphamide, azathioprine, and mycophenolate, for neurologic/immunologic paraneoplastic syndromes if no improvement after 2-4 weeks 9, 12
• The Endocrine Society recommends treatment of ectopic Cushing Syndrome, which occurs in 1.6-4.5% of SCLC, with a focus on cancer therapy and syndrome-specific interventions based on severity 13

Critical Management Principles

• The National Comprehensive Cancer Network recommends balancing cancer treatment timing with paraneoplastic syndrome control, with paraneoplastic syndrome workup performed in parallel with cancer diagnosis and staging to minimize delays 9, 10
• The American Society of Clinical Oncology suggests that response to cancer therapy favorably affects the course of paraneoplastic syndromes, and that concomitant immunotherapy does not adversely affect malignancy outcomes 9, 10, 12

Management of Paraneoplastic Syndrome Symptoms

Immediate Diagnostic and Treatment Approach

• The American College of Chest Physicians recommends performing paraneoplastic syndrome evaluation in parallel with cancer diagnosis and staging to minimize delays in definitive cancer treatment 14
• Obtaining hemoglobin, electrolytes, liver function tests, and calcium levels is part of the initial evaluation for paraneoplastic syndromes 15
• Balancing the benefits of treating the paraneoplastic syndrome against potential harms of delaying cancer treatment is crucial 14

Treatment Algorithm by Mechanism

• The American College of Chest Physicians suggests that treating the underlying malignancy is the most important approach, as successful tumor therapy often improves paraneoplastic symptoms 14
• Corticosteroids are recommended as first-line therapy for dermatomyositis, with options to add methotrexate, cyclophosphamide, azathioprine, mycophenolate, rituximab, or IVIg for refractory cases 14
• Immunosuppressive therapy improves symptoms of dysautonomia, orthostatic hypotension, and cardiac arrhythmia in autoimmune autonomic ganglionopathy 16, 14
• Cyclophosphamide, azathioprine, and mycophenolate are options for second-line immunotherapy if no improvement is seen after 2-4 weeks 14

Critical Management Principles

• Treating the underlying malignancy is the primary therapy, and concomitant immunotherapy does not adversely affect malignancy outcomes 14
• Paraneoplastic syndromes may have an adverse impact on cancer treatment, requiring rapid control before proceeding with definitive cancer therapy 15
• Sometimes, treatment and control of paraneoplastic syndromes will require a delay in cancer treatment initiation 14

Prognosis and Expectations

• Most paraneoplastic symptoms are reversed after tumor resection, but neurologic syndromes may have permanent sequelae 17